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Summary: The basic proteinase inhibitor from bovine or­
gans, aprotinin (active ingredient of TrasyloP) has been ex­
tensively studied with respect to its chemical, physical and 
biochemical properties and its inhibitory mechanism of ac­
tion. It is widely used as a valuable tool for studying protein/ 
protein interactions and protein conformation at the mole­
cular level. There are numerous examples of the usefulness 
of aprotinin in biochemical and biomedical research. It has 
also become a valuable drug for the treatment of various 
diseases like, e.g. hyp er fibrinolytic hemorrhage and trauma­
tic-hemorrhagic shock. 
The purpose of this paper is threefold. It summarizes our 
present knowledge of the subject in various disciplines; it 
provides the active scientist with basic data for his experi­
mental work; and above all it points the way to future direc­
tions of aprotinin research. 
Zusammenfassung: Biochemie und Anwendung des Kalli­
krein-Inhibitors Aprotinin aus Rinderorganen 
Der basische Proteinase-Inhibitor Aprotinin (Wirkstoff von 
TrasyloP) aus Rinderorganen wurde hinsichtlich seiner che­
mischen, physikalischen und biochemischen Eigenschaften 
sowie seiner Reaktionsweise mit Enzymen eingehend unter­
sucht. Aprotinin dient heute allgemein als wertvolles Agens 
zum Studium der Wechselwirkungen von Proteinen und der 
Protein-Konformation auf molekularer Basis. In zahlreichen 
Anwendungsbeispielen in der biochemischen und biomedi­
zinischen Forschung wurden mit Hilfe des Aprotinin rich­
tungsweisende Erkenntnisse gewonnen. Aprotinin hat sich 
auch als potenter Wirkstoff zur Behandlung verschiedener 
Krankheiten erwiesen, so ζ. B. bei hyperfibrinolytischen 
Blutungen und beim traumatisch-hämorrhagischen Schock. 
Der vorliegende Artikel dient einem dreifachen Zweck: Er 
faßt den gegenwärtigen Erkenntnisstand in den verschiede-
nen Fachdisziplinen zusammen, er bietet dem experimentell 
tätigen Wissenschaftler Basisdaten für seine Versuchsvorha-
ben und er gibt Hinweise für neue Zielsetzungen, die mittels 
Aprotinin angegangen werden können. 
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1. Introduction: Discovery, distribution and isolation 
Aprot in in 2 ) was independently discovered by Kraut et al. [1] 
as a kall ikrein "inactivator" in bovine lymph nodes, and by 
Kuni tz and Northrop [2] as a trypsin inhibitor in the bovine 
pancreas. Later, Werle et al. also found kall ikrein-inhibit ing 
activities in extracts o f other bovine organs, such as the lung, 
parotid gland, spleen, liver, pancreas, and seminal vesicles. 
Lower activities were found in the thyroid gland, kidney and 
mucous membranes o f the trachea and esophagus, and in ex-
tracts from the same organs of sheep and goat [3 -6 ] . More 
recent investigations have shown that this kal l ikrein-
inhibi t ing activity is due in most, i f not a l l , cases to the pres-
ence of aprotinin or aprotinin-like inhibitors in these tissues 
[ 5 - 7 ] . 
In addition, aprotinin has been found in the following bo-
vine organs or tissues: Ovary [8], heart, thyroid, posterior p i -
tuitary, and the rumen mucosa [9] as well as in cartilage and 
aorta [10]. Remarkably, the two latter tissues are known to 
be highly resistant to tumor invasion. Recently, Hoch-
strasser and Wächte r discovered aprotinin-like inhibitors as 
components of the human and bovine inter-a-trypsin inh ib i -
tor [11] and in free form in bovine serum [12]. 
O f special interest, in view of its biological function [13] is 
the occurrence o f aprotinin in mast cells, detected by the i n -
direct immunofluorescence technique [13, 14], and its beha-
vior as an intracellular compound [4, 5]. The mast cell o r i -
gin o f aprotinin is indicated also by a similar distribution 
pattern: organs known to contain high numbers of these 
connective tissue cells are also rich in aprotinin (especially 
lung, parotis and pancreas) and vice versa. Possibly, apro-
t in in is involved in the regulation of mast cell proteinase 
activities [13]. 
For commercial purposes, aprotinin is isolated by classical 
methods such as fractional precipitation, gel filtration and 
ion exchange chromatography, being extracted solely from 
bovine lung, pancreas and parotid glands [5]. These tissues 
contain approx. 1500 K I U (= biological kallikrein units) 
(lung) or 400 K I U (pancreas, parotid gland) per gram wet 
weight [4, 5]. For the rapid purification of aprotinin or 
aprotinin-like inhibitors on a laboratory scale in good yields 
(up to 90%), acidic extraction followed by affinity chromato-
graphy on water-insoluble enzyme derivatives (e.g. trypsin-
Sepharose or trypsin-cellulose) is the method of choice [8, 
15]. On the other hand, water-insoluble aprotinin deriva-
tives are widely used for the isolation of proteinases (see sec-
t ion 6.1.). 
2 ) Aprotinin is also known as bovine pancreatic trypsin inhibitor 
(Kunitz) (BPTI) and trypsin-kallikrein inhibitor (TKI); it is the 
active ingredient of Trasylol®, a drug registered in the name of 
Bayer Leverkusen (FR Germany). In some countries Kallikrein is 
a registered trademark of Bayer. 
Fig. 1: Primary structure of aprotinin according to Kassell and Laskowski 
[17] and Anderer and Hörnle [18]. The inhibitor molecule consists of a single 
polypeptide chain of 58 amino acid residues cross-linked by 3 disulfide 
bridges. 
2. Structure and physicochemical properties 
2.1. Structural characteristics 
Aprot inin , a polypeptide w i th a molecular weight o f 6,51 2, 
is obtainable in crystalline form [2, 16]. It consists of 58 
amino acid residues that are arranged in a single polypepti de 
chain. This chain is cross-linked by three disulfide bridges, 
one of which (Cys-14-Cys-38) is readily split by reducing 
agents. The primary structure of aprotinin is shown in Fig. 1 
[5, 17, 18]. 
Information on the three-dimensional structure was ob-
tained by X-ray crystallography, which revealed a pyr i form 
molecule (Fig. 2) [19, 20]. The polypeptide chain is folded so 
that the hydrophobic radicals are concentrated in the inte-
rior of the molecule, whereas all of the hydrophilic radicals, 
except for the side chain Asp-43, are on the outside which is 
exposed to the aqueous environment. This arrangement re-
sults in a very compact tertiary structure and is mainly re-
Fig. 2: Tertiary structure of aprotinin according to Huber et al. [19] 
and Deisenhofer and Steigemann [20]. The molecule has a length of 
about 29 A, a diameter of 19 Ä, and contains a double-stranded antiparallel 
/?-sheet (from Ala-16 to Gly-36), twisted to form a right-handed double helix 
with 14 residues per turn. Amino acid residues included in the hatched area 
are in close contact with the enzyme in the trypsin-inhibitor complex. Resi-
due number 19 is not included in this contact region, but its basic nature may 
be important for kallikrein inhibition in some cases; cf. Table 4 and Section 
4.3. 
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sponsible for the remarkable stability o f aprotinin against 
denaturation by high temperature, acids, alkalies and organ­
ic solvents or proteolytic degradation [21]. 
Other interesting features are: (i) The highly dipolar char­
acter of aprotinin due to concentration of the negatively 
charged radicals at one end of the molecule, viz. the bottom 
of the pear (see Fig. 2); and (ii) the strong basicity of the 
aprotinin molecule, wi th an isoelectric point close to 10.5 
[21]. 
2.2. Stability, optical data and behaviour in dialysis 
Apro t in in can be heated for a short time in dilute acid at 
100 e C or i n 2.5% trichloroacetic acid at 80 °C without los­
ing any activity. It can be exposed to solutions with extreme 
pH-values ranging from 1 to 12.6; inactivation begins at p H 
12.8 at room temperature [21]. These data were obtained by 
various methods, such as inhib i t ion studies [21], N M R (nu­
clear magnetic resonance), and Raman measurements [22]. 
Apro t in in may be kept in a salt or buffer solution, e.g. 0.15 
mol/1 NaCl , at room temperature for at least 18 months 
without any loss of activity. The inhib i tor is also stable and 
soluble in water, 70% (v/v) methanol, 70% (v/v) ethanol, 
and 50% (v/v) acetone [21]. 
Another outstanding property of aprot inin is its uncommon 
stability to proteolytic degradation by other proteinases [7, 
21]. So far, only thermolysin has been found capable of d i ­
gesting "nat ive" aprotinin after heat labilization at 60-80 °C 
[23]. 
In a 1 mg/ml solution of aprotinin, absorption of A = 0.84 
occurs at 280 nm (1 cm light path), relatively independently 
of p H [21]. In the presence of bactericidal agents, the inhibi ­
tor concentration should be optically determined at an alka­
line p H . The absorption maximum of aprotinin is then shift­
ed from 277 nm at p H 7 (specific absorbance: 0.89 cmVmg) 
to 297 n m in 0.1 Ν N a O H (specific absorbance: 1.32 
cmVmg), thus differing from the absorption range of the 
commonly used preservatives (Arens, Α., 1970, unpublished 
data). 
Owing to its low molecular weight and high basicity, apro­
t in in penetrates or adheres to the commonly employed dia­
lysis tubes. I t is advisable, therefore, to use either acetylated 
material [24] or ultrafiltration membranes with an exclusion 
l imi t o f 5000 daltons. Small quantities of aprotinin should 
be kept in suitable salt solutions (e.g. in volatile buffers) to 
avoid adsorption of the inhibitor on negatively charged sur­
faces during dialysis or filtration through columns (e.g. Se-
phadex). 
3. Inhibitory characteristics and biological aspects 
3.1. Units and assays 
Apro t in in is often called a "broad-specificity inhibi tor" as 
an expression of its ability to inhibi t various proteinases 
such as those listed in Table 2. The "kal l ikre in inactivator 
u n i t " ( K I U or KIE) is in worldwide use as a measure of 
aprotinin activity and is accepted as such [3 -7 ] . One K I U is 
defined as that amount of aprotinin which decreases the 
activity of two biological kall ikrein units ( K U ) by 50%. (One 
K U is defined as that amount of kall ikrein which, when i n ­
jected intravenously, causes the same decrease in dog carotid 
blood pressure as 5 m l of urine taken from 50 L , collected 
from healthy human individuals and dialyzed for 24 h 
against running tap water [3, 4]. This unit is also known as a 
Frey unit for F U [1 , 3]). 
As the biological assay is tedious to perform and has a high 
standard deviation, enzymatic assays with synthetic sub­
strates are preferable. Compared wi th kallikrein, inhibit ion 
of trypsin by aprotinin (expressed in μτηοϊ o f substrate turn­
over inhibited in unit time) proceeds much more rapidly 
and the resulting titration curve is linear over nearly the 
whole range, i.e. up to 90% inhibi t ion of the applied amount 
of enzyme. Therefore, trypsin inhibi t ion tests are advanta­
geous and commonly used for the assay of aprotinin. The 
Enzyme Commission of the FIP (Federation Internationale 
Pharmaceutique) recommends a t i tr imetric assay in which 
Table 1: Conversion factors between the various units or inhibitor units (IU) 
that are recommended or used to express the inhibitory activity of aprotinin. 
Units or inhibitor units are defined as the reduction in substrate turnover, ex­
pressed in μιηοΐ per time interval, caused by aprotinin as compared with an 
inhibitor-free control sample. 
Units 
wanted 
Units given 
K I U a ) 
biol. 
assay 
F.l.P. unitsb) 
(μπιοί 
BAEE/min) 
^kat c) 
(//mol 
BAEE/s) 
I U d ) ΒΑΡΑ 
(μηιοί 
ΒΑΡΑ/min) 
K I U a ) χ 1 x30 χ 1800 x615 
F.l.P. 
units b) χ 1/30 χ 1 χ 60 χ 20.5 
//kat c) χ 1/1 800 χ 1/60 χ 1 χ 1/2.93 
IUßAPA χ 1/615 χ 30/615 
(= 1/20.5) 
χ 1800/615 
(=2.93) 
1 
a ) "Kallikrein inactivator unit" based on a biologic assay, see text. 
b ) Units based on a titrimetric assay with BzArgOEt (BAEE) as (hog) trypsin 
substrate as recommended by the Enzyme Commission of the Federation 
Internationale Pharmaceutique (F.I.P.); see text. 
c ) Units recommended by the NC-IUB (Nomenclature Committee of the In­
ternational Union of Biochemistry), Eur. J. Biochem. 97, 319 (1979). 
d ) Inhibitor units based on a photometric assay with BzArgpNA (ΒΑΡΑ) as 
substrate and porcine trypsin as enzyme, see text. 
residual trypsin activity is determined wi th BzArgOEt ( N a -
benzoyl-L-arginine ether ester, also BAEE for short) as the 
substrate under conditions specified by the I U B (Internation­
al U n i o n of Biochemistry) [25, 26]. The conversion factors 
between the various recommended units are given i n Table 
1. Highly purified aprotinin free of water and salt ist found 
to have a specific activity o f 7,150 ± 200 K I U / m g or 0.14 
/ / g / K I U . 
A photometric assay is also very useful for practical pur­
poses. In this test, trypsin inhibi t ion by aprotinin is deter­
mined by means o f BzArgpNA (N*-benzoyl-arginine-p-
nitroanilide, also Β Α Ρ Α for short) as the substrate at 405 nm 
[21, 27]. The racemic substrate mixture D , L - B A P A (0.77 
mmol/1) previously used in this assay should be replaced by 
L-BAPA (0.383 mmol/1). Inhibi t ion of trypsin by the D -
form and solubility problems frequently encountered wi th 
the mixture of the two enantiomers are then avoided [28]. 
The biological units ( K I U ) can be calculated from the inh i ­
bitor units that are obtained wi th porcine trypsin and L -
B A P A as substrate by the equation: IUBAPA (μπιο ί / 
min) χ 615 = K I U (see Table 1). 
W i t h the photometric assay (substrate L-BAPA) about 
60-300 pmol aprotinin (in a given concentration o f approxi­
mately 0.6-3 yumol/l) and wi th the t i tr imetric assay (sub­
strate BAEE) up to twice this amount or concentration of 
aprotinin can be measured under the conditions given i n the 
Appendix. Whereas the photometric assay is especially suit­
able for determination of aprotinin concentrations, the 
t i tr imetric assay is the method of choice i f optimal condi­
tions for enzyme catalysis are required. Principally, trypsin 
inhibi t ion by aprotinin may be assayed also wi th more en­
zyme-specific chromatogenic ("chromogenic") or fluoro-
genic peptide substrates [29, 30]. However, due to the higher 
sensitivity (approx. 10- to lOOfold) reached wi th such sub­
strates, complex formation may proceed more slowly and 
the range of the linear part of the t i t rat ion curve may 
be smaller, both effects being o f disadvantage for practical 
purposes. The same holds true i f instead o f trypsin inh ib i ­
tion tissue kall ikrein inhibi t ion is determined by means o f 
a chromogenic or fluorogenic peptide substrate, e.g. D -
ValLeuArg-p-nitroanilide [31] or ProPheArg-4-methyl-cou-
maryl-7-amide [32]. A kall ikrein inhibi t ion assay (preferably 
wi th D-ValLeuArg-p-nitroanilide = S-2266 [31]) may be ad­
vantageous, however, i f aprotinin has to be quantified i n tis­
sue extracts or body fluids containing i n addition naturally 
occuring trypsin inhibitors. In such cases the influence o f the 
extracts on kal l ikrein activity also has to be considered and 
control samples wi th known aprotinin concentrations should 
be used as a reference standard ( M . Jochum and H . Fritz, 
manuscript in preparation). Note, kal l ikrein inhibi t ion alone 
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does not prove the presence of aprotinin in a test sample; for 
unequivocal identification of aprotinin at least the inhibi t ion 
ratio towards its major target enzymes (trypsin, chymotryp-
sin, plasmin, plasma kallikrein and tissue kall ikrein; cf. Ta­
ble 2) has to be detected i f specific immunological methods 
are not available. 
In lieu of synthetic substrates, use may be made of the na­
tural kallikrein substrates, the kininogens, for the assay o f 
aprotinin activity based on kallikrein or trypsin inhibi t ion 
[33]. When plasmin inhibi t ion is assayed as described pre­
viously [34], 1 antiplasmin unit (APU) corresponds to 40 
K I U of aprotinin. A radioimmunoassay technique devel­
oped by Fink and Greene permits specific detection o f m i n ­
imal quantities o f aprotinin in biological fluids or tissue ex­
tracts [35]. 
3.2. Inhibitory specificity and biological aspects 
The most striking feature of aprotinin is its broad inhibitory 
specificity. Besides trypsin and chymotrypsin, i t strongly i n ­
hibits plasmin as well as kallikreins of different origin (Ta­
ble 2) [ 3 - 7 , 2 1 ] . 
In view of the therapeutic uses of aprotinin and its use i n 
both clinical and experimental animal studies, its species 
specificity is o f particular interest. Several investigators have 
found that various tissue kallikreins (from pancreas, sub­
mandibular glands, kidney or urine, and colon) as well as 
plasma kallikreins from man, pig and cattle are inhibited by 
aprotinin, whereas the corresponding guinea pig kallikreins 
are not inhibited [ 5 - 7 ] . Divergent results have repeatedly 
been obtained wi th mouse, dog and rat kallikreins [7]. Re­
cently, however, it was shown that urinary kallikreins of the 
rat are very effectively inhibited by aprotinin [48]. 
The therapeutic uses of aprotinin are based on its inhibi t ion 
of human trypsin, plasmin and plasma, tissue or urinary 
kall ikrein. It should be noted that plasmin and tissue ka l l i ­
kreins are inhibited to a decidedly greater extend than the 
plasma kall ikrein (Table 2). 
The inhibi t ion o f human pancreatic proteinases by aprotinin 
is of special interest in connection wi th the therapeutic use 
o f the drug Trasylol in acute pancreatitis. Human cationic as 
well as anionic trypsin is strongly inhibited by aprotinin [49, 
50]. Human chymotrypsin I I is not inhibited at al l , while 
aprotinin appears to have a fairly low affinity for human 
chymotrypsin I and protease Ε [49]. Protease Ε is quite simi­
lar to porcine pancreatic elastase [51], but not to the " t rue" 
(i.e. elastin-digesting) human pancreatic elastase [52]. The 
affinity of aprotinin for human pancreatic kallikrein has not 
been quantitatively estimated. I f the relation between tissue 
and urine kallikreins in man [44] is as close as that between 
tissue and urine kallikreins in the pig [53], aprotinin would 
Table 2: Dissociation constants Kj of enzyme-aprotinin complexes. 
Enzyme Kj (mol/1) pH Reference 
Trypsin, bovine 6.0 χ ΙΟ" 1 4 8.0 [36] 
Anhydrotrypsin, bovine < 3 x l O - 1 3 8.0 [36] 
Trypsinogen, bovine 1.8 χ 10-6 8.0 [37] 
Chymotrypsin, bovine 9.0 χ 10"9 8.0 [36] 
6.0 χ ΙΟ-9 7.2 [38] 
Plasmin, porcine 4 χ 10' 9 a) 7.8 [39] 
human 2.3 χ 10- 1 0 a) 7.8 [40] 
1.0 χ 10-9 7.3 [41] 
Kallikrein 
pancreatic, porcine 1 χ 10' 9 a) 8.0 [39] 
pancreatic, porcine 1.3 χ 10"9a) 9.0 [42] 
submand., porcine 1.6 χ 10- 9 a) 9.0 [42] 
urinary, porcine 1.7 χ 10"9a) 9.0 [42] 
plasma, porcine 1 χ 10"7 7.8 [43] 
urinary, human 0.9 χ ΙΟ" 1 0 8.0 [44] 
plasma, human 3 χ I0" 8 8.0 [45] 
Elastase, human leukocytes 3.5 χ 10"6 b) 8.0 [46] 
Urokinase, human urine 8.0 χ 10"6 8.8 c ) 
a ) Approximate values estimated from titration curves according to Green 
and Work [47]. 
b ) Highly dependent upon ionic strength [46]. 
c ) Dietl, T., Hugo, B., Fritz, H., unpublished data (1980). 
have a rather strong affinity also for human pancreatic ka l ­
likrein [54] (Table 2). Remarkably, rat chymotryps in , l ike 
human chymotrypsin I I , is not inhibited by apro t in in [55]. 
Appreciable amounts o f elastase and cathepsin G are re­
leased from human polymorphonuclear granulocytes during 
inflammations [56-58] . The affinity o f aprot inin for these 
leukocytic neutral proteinases is therefore of considerable 
medical interest. Both elastase and cathepsin G have been 
shown to enter into specific reactions w i th apro t in in , but the 
dissociation constants Kj for the resultant enzyme-iehibi tor 
complexes are quite high [46, 59-61] (Table 2). Cathepsin G 
seems to be inhibited by aprotinin to a very sma l l extent 
[61]. Aprotinin-Sepharose nevertheless proved to be a very 
suitable affinity adsorbent for isolation o f both elastase and 
cathepsin G (see section 6.1.). 
Aprot inin has a relatively low affinity for the t rypsin- l ike 
enzyme of spermatozoa, acrosin [62, 63]. Consequently, i n ­
hibition o f this enzyme by aprotinin in vivo, hence preven­
tion of fertilization, seems not to be practicable [64]. On the 
other hand, a trypsin-like or kall ikrein-l ike proteinase o f the 
rabbit blastocyst is strongly inhibited by aprot inin [65] . 
Interestingly enough, human urokinase, too, is inh ib i ted by 
aprotinin, i f rather weakly (Table 2; Die t l , T., Hugo, B., and 
Fritz, H . , 1980, unpublished data). As urokinase m a y origi­
nate from plasminogen activators [66], there may also be a 
weak specific interaction between aprotinin and these tissue 
proteinases though this has not been reported thus far. Ow­
ing to the high affinity o f aprotinin for plasmin, the inh ib i tor 
also reacts wi th the streptokinase-plasmin complex, progres­
sively inhibiting its fibrinolytic activity, which is not inhibi t ­
ed by plasma proteinase inhibitors [41]. 
More recent observations indicate that aprotinin is also a 
strong inhibitor of the arginine esterases o f growth factors 
[67, 68]. This is actually not surprising inasmuch as these 
proteinases show a striking similarity to the tissue kal l ik­
reins [69, 71]. The biological significance o f this discovery is 
still unknown. 
As for the substrate specificity o f these proteinases, we may 
assume that the inhibitory specificity o f aprotinin is mainly 
restricted to enzymes wi th trypsin-like substrate specificity 
and trypsin-like tertiary structures in the vicini ty o f the ac­
tive site. Chymotrypsin seems to be an exception meeting 
the latter but not the former requirement. The same holds 
true for granulocytic elastase and cathepsin G. O f pr imar i ly 
theoretical interest are recent observations which suggest 
that aprotinin also forms equimolar complexes w i t h enzy-
matically inactive anhydrotrypsin [36] and trypsinogen [37, 
72], respectively. 
Many proteinases and other enzymes that have been tested 
are not inhibited by aprotinin, viz. (porcine) pancreatic 
elastase, thrombin, enterokinase, subtilisin (Bacillus subtilis 
protease A and B), Aspergillus oryzae protease, papain, f i -
cin, clostripain, thermolysin, pepsin, renin, angiotensin-con-
verting enzyme, angiotensinase, carboxypeptidase A and B, 
ribonuclease, lysozyme, liver esterase, and ribosomal poly­
peptide chain elongation factors [7, 21]. 
3.3. Inhibition mechanism and kinetic constants 
As a rule, the active site of the enzyme is blocked by com­
plex formation with aprotinin (see section 4). I f the esterolyt-
ic or amidolytic activity of the enzyme is inhibited as a re­
sult, its proteolytic activity is also inhibited, and vice versa 
[73]. In the case of components forming firm complexes, 
such as trypsin, plasmin or tissue kal l ikrein and aprotinin, 
the degree of inhibit ion is normally independent o f the sub­
strate used for the inhibit ion assay. However, i f (1) the affini­
ties of inhibitor and substrate for the enzyme are o f similar 
magnitude [43] - the respective Kj and K m values are suitable 
criteria - or (2) i f the lifetime of the aprotinin-enzyme com­
plex is short when compared with the length o f the assay 
procedure [74], the observed degree o f inhibi t ion may de­
pend on the substrate and assay conditions applied. Exam­
ples are (1) the system plasma kall ikrein/BzArgOEt/aproti-
nin [43], and (2) the systems starfish trypsin 1/BzArgpNA 
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or 4-metIhylumbelliferyl p-guanidinobenzoate (GdnBzMum)/ 
apirot inin [74]. Whereas no inhibit ion of starfish trypsin 1 by 
apirot inm is seen wi th BzArgpNA as the substrate, complex 
forrmationi is clearly demonstrable by burst titration with 
GdinBzMuim. 
I n h i b i t i o n by aprot inin is always competitive and reversible, 
as (expressedi>y Equation (a) [75—78]l 
E + 1 A L A C i i x ^ E + P (a) 
Ik. ii k. 2 k c · k x 
whiere Ε Is the proteinase; I and I * are the virgin (reactive-
sitce Lys-115-Ala-16 bond intact) and modified (reactive-site 
boma hydrolyzed) inhibitor, respectively; L and X are loose, 
inttermediate precomplexes preceding the stable complex C. 
(Otther nomenclatures use k 3 for k . c , k.3 for kc, \u for k . x , k.4 
forr k x , and L * for X . However, as the nature of the com-
pleexes L and L * turned out to be^quite different [77, 78], we 
preefer the nomenclature used in Eq. (a) above.) 
In the first step from either side (kj or k x ) , a fast second-
orcder reaction, a relatively loose complex L (Michaelis-
Meenten complex) or X is formed, followed in the rate-
dettermining step (k 2 or k c ) , a slow first-order transition, by 
forrmation of the stable complex C. Rate constants (meas-
ureed at p H 7.5 and 22.5 °C) for the various steps of the 
reaactiorn o f aprot inin with bovine trypsin (try) or bovine 
crnymotrypsin (chy) are given by this system of equations 
[755-78]: 
try chy try chy 
5 x l 0 6 - 1 0 8 8 x 10 6-10 8 M-'s' 1 Ϊ 25 350 s"1 
EE +1 ^ L ^ 
2 x l 0 3 - 4 x l 0 4 4 x l 0 3 - 5 x l 0 4 s"1 ~ 8xl0" 8 9xl0" 4 s"1 
try chy try chy 
3.3xlO" 1 0 5xl0" 9 s"1 0.35 0.26 s"1 
(C , X ^ - E + I * 
~ Ix lO" 2 5xl0* 4 s"1 105 4 x l 0 3 M" 1 s"1 
Thie fol lowing rate constants have recently been reported 
[411] for the reaction o f aprotinin wi th plasmin: k| = 9 χ 105 
M-^s- 1 and k 2 = 1.4 χ 103 s-1. The difference in reaction rates 
maay be illustrated by the fact that in the binding of aprotinin 
to α -chymot ryps in , the precomplex L , which has a life vary­
i n g between 2 χ Ι Ο 4 and 2 x IO- 5 s, is destroyed 10 to 100 
tirmes before a single reaction to complex C takes place [76]. 
O m the other hand, the rate constants k 2 and k c for the 
mconomolecular reaction which leads to C from the two 
sidles, L and X , differ by a factor of 106 for bovine chym-
otrrypsin [77]. 
Off pr imary interest for practical purposes are kinetic con­
stants that describe overall reactions of a given system. 
Eqiuation (b), a simplification of the enzyme-inhibitor inter­
ac t ion , may prove adequate [36, 75]: 
E + I ^ C ^ ^ r E + I * (b) 
\CA k* 
where k o n or k j n are the second-order rate constants o f asso­
ciation (M- 1 s 1 ) ; k d is the first-order rate constant o f disso­
ciation (s- !); 
kd cone. Ε χ cone. I 
K i = - — = ~ 
k o n cone. C 
is the overall equil ibrium (dissociation) constant (mol/1) for 
the liberation o f the virgin inhibitor I , and K f that for the 
formation of the modified inhibi tor I * ; t./2 is the half-life o f 
dissociation o f complex C. For definition and symbols, see 
[36, 75-77] . 
Typical kinetic constants for the reaction of aprotinin wi th 
proteinases are presented in Table 3. The association rate 
constants k o n given indicate that virgin aprotinin rapidly 
reacts with the proteinases to form a stable complex C, 
which means that the preincubation times ordinarily used in 
the inhibit ion assay (5-15 min before addition o f substrate) 
are sufficient for complex formation to occur. The dissocia­
t ion constants kd, however, show significant differences be­
tween aprotinin-enzyme complexes, wi th half-lives ranging 
from 17 weeks (bovine trypsin) to 11 seconds (starfish t ryp­
sin 1). The very low kd-value o f the bovine trypsin-aprotinin 
complex is the main reason for the extremely high stability 
o f this complex as reflected in the dissociation constant K i = 
6 χ 10- 1 4 mol/1, which is one of the lowest so far reported for 
a protein/protein interaction [36]. Although the equil ibrium 
constant of the starfish trypsin 1-aprotinin complex is also 
rather low (Kj = 1 χ I Ο-9 mol / I ) , i t dissociates 106 times 
more rapidly (t 1 / 2 = 11 s) than the former owing to the high 
dissociation rate constants kd = 6.5 χ 10-2s-' and k.c = 
2 x l 0 - 3 s-1 as compared wi th k d = 6.6 χ 10-8 s-1 for the com­
plex wi th bovine trypsin (see Table 3) [74, 79]. 
Another observation is of special interest i n this connection. 
Ordinari ly, the incubation o f a proteinase inhibitor protein 
wi th catalytic quantities of a target enzyme results in specific 
hydrolysis of the reactive-site peptide bond so that an equil i­
b r ium is reached between the virgin and the modified inhib i ­
tor, as is shown in Eq. (a) and defined by Eq. (c) [73, 75]. 
Khyd = cone IVconc I (c) 
In the case of aprotinin, cleavage of the reactive-site bond 
Lys-15-Ala-16 by commonly available serine proteinases is 
an extremely slow process (cf. the extremely low k . c values 
for the complexes of aprotinin wi th trypsin and chymotryp­
sin in Table 3). It therefore remained undetected unti l re­
cently, when an equil ibrium constant Khyd o f 0.3-0.38 (at 
p H 5-7.5 [77]) could be established after nearly a year's 
incubation wi th plasmin [80]. The observation that rapid 
dissociation of proteinase-inhibitor complexes (high k.2 val­
ue) may be correlated wi th rapid hydrolysis of the reactive-
site peptide bond (high k . c ) [81] prompted a search for pro­
teinases suitable for the production of modified aprotinin. 
Trypsin 1 from the starfish Dermasterias imbricata proved 
to be well-suited for this purpose [74]. It catalyzes both the 
hydrolysis and the resynthesis of the reactive-site peptide 
T a t b l e 3: Overall rate constants for formation and dissociation of enzyme-aprotinin complexes. For details and definition of constants, see text, especially equa­
tion! (b) (Kj or Kf, kon, k d , kon , t>/2) and equation (a) (k.2, K_c). For definition, Μ = mol/1. 
Complex with 
Conditions Rate constants and half-lifes 
Reference 
pH Τ CC) Kj(M) K,*(M) kon ( M - 1 ^ ) kdis"1) kSn ( M - V 1 ) k-c (s-1) t * b ) 
Tryypsin, bovine 8 
8 
7.5 
7.5 
25 
21 
22.5 
21 
6x l0" 1 4 
~ I x I 0 " 1 3 
~3x lO" 1 3 ~ IxIO" 1 3 
l . l x l O 6 
2 x lO 5 
3 x lO 5 
6.6xl0" 8 
1 x l0" 7 a ) 
~8 x l 0 8 a ) 
8 xlO" 8 
3 x l 0 3 3.3xlO- 1 0) 
8.7χ10- 1 0 ί 
17 weeks [36] 
[75] 
[78] 
[79] 
Amhydrotrypsin 8 25 <3x lO" 1 3 7.7xl0 5 < 2 xlO" 7 > 5 weeks [36] 
Crnymotrypsin, bovine 8 
7.5 
7.5 
25 
22.5 
21 
9xl0- 9 
2xl0" 9 7.6x10-'° 
l . l x l O 5 
6 x lO 5 
1 xlO" 3 
9 x l0" 4 a ) 
9 x l0" 4 a ) 
8.5 5.4x10"9 ) 
1.4xl0"8 ) 
12 min [36] 
[77] 
[79] 
Tryypsin 1. starfish 7.8 21 IxIO" 9 6.5x10-2a) 2 xlO" 3 ) 11 sec [74, 79] 
') IKL2 in equation (a), normally practically identical with kd. 
') 1 Half-life of dissociation. The half-life of association (tljp) is concentration-dependent. For the reaction of excess native aprotinin with trypsin ( I x I O - 7 mol/1) 
ttfyf -6 .3 s, and with chymotrypsin ( I x I O - 7 mol/1) ti)f ~ 63 s; for the reaction of modified aprotinin (I*) the corresponding values are ίψ ~ 39 min (trypsin) 
;and tt)p ~ 9.5 days (chymotrypsin), respectively, at the same enzyme concentration. (Calculated from the values given in Table 3 by F. Fiedler, Munich). 
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bond approximately 106 times more rapidly than bovine 
trypsin [79]. Incubation of aprotinin wi th 0.2 moi% o f tryp­
sin 1 at 21 °C at a p H between 6.2 and 7.8 resulted in an 
equil ibrium constant K h y d close to 1, corresponding to equi-
molar amounts of virgin and modified inhibitor i n the incu­
bation mixture. This constant increased exponentially with 
increasing p H ( K h y d ~ 2.4 at p H 8.5 and K h y d ~ 4.5 at p H 
8.9) [79]. A t p H 8.2, the equil ibrium was reached after 4.6 
days, starting either from virgin or from modified aprotinin. 
Besides the decidedly higher (approx. 104 times) dissociation 
rate (see k d in Table 3) of the aprotinin-chymotrypsin com­
plex as compared wi th the aprotinin-trypsin complex, there 
are striking differences in the global association rates for the 
formation o f the stable complex C from either virgin or mo­
dified aprotinin (Table 3). The reaction o f the modified inhi ­
bitor wi th chymotrypsin and trypsin proceeds much more 
slowly (by a factor of 105 and 10 2, respectively) than with 
virgin aprotinin (k* n = 8.5 and 3 x l 0 3 MM s-' vs k o n -
6 χ 105 and 3 χ 105 s-1, respectively) [77, 78]. This is o f prac­
tical significance in that the two inhibitors may be quantita­
tively estimated in mixtures preincubated for different 
lengths of time. Whereas, for example, 99.9% of native 
aprotinin but less than 0 .1% o f modified aprotinin com­
plexes wi th chymotrypsin, under suitable conditions, wi th in 
1 min , both inhibitor forms are totally complexed wi th tryp­
sin after 2.5 h of preincubation [79]. 
The following observations are also of general interest: (1) 
A n y chemical modification of the ion pair formed between 
Lys-15 of aprotinin and Asp-177 of trypsin in the specificity 
pocket results in a significant increase (10 3 times or more) in 
the dissociation rate o f the complex [36]. The marked differ­
ence between the stability of the trypsin-aprotinin complex 
and that o f the chymotrypsin complex (see Table 3) is main­
ly due to the additional, stabilizing interactions afforded by 
the specificity pocket for Lys-15 [36, 77]. (2) The formation 
of a very tight complex between aprotinin and anhydrotryp­
sin (Table 3) clearly shows that the alcohol side chain of 
Ser-183 of trypsin plays no role i n the stabilization of the 
complex [36]. (3) The absolute values of free energy o f asso­
ciation are very high for the f i rm complexes, e.g. AG\ = 
-18 .1 and - 1 1 kcal/mol for the complex wi th trypsin and 
chymotrypsin, respectively, whereas the enthalpic values 
CdH e) are near zero (25 °C, p H 8.0) [36]. 
τ τ ι ι 1 1 1 1 
4 5 6 7 θ 9 10 pH 
Fig. 3: pH dependence of the apparent rate constant of association 
kon (left ordinate) and of the dissociation equilibrium constant Ki (right ordi­
nate) of the system aprotinin/a-chymotrypsin. Taken from Engel et al. [76]. 
The p H of the medium has a significant effect on the rate 
and equilibrium constants shown i n Table 3 and 2 and on 
Khyd. Normally, the equilibrium constants K j and Khyd as 
well as the dissociation rate constants kd and k_c are lowest 
in the neutral and slightly alkaline p H range ( p H ~ 7-9) , 
whereas the association rate constants k o n and kjn then have 
the highest values. Accordingly, complex formation is 
strongly favored at the optimal p H o f the proteinases. As the 
p H of the medium decreases, K i and kd or k_c increase 
sharply, whereas k o n or k£ n decrease significantly so that 
dissociation of the complex is promoted in acidic media. 
The Kj of the pig pancreas kall ikrein-aprotinin complex, for 
example, increases by a factor of 10 3 from p H 7.8 to 5; at 
p H 4 the complex is completely dissociated [4] . The Kj o f 
the bovine trypsin-aprotinin complex increases approxi­
mately 108 times from p H 8 to p H 3 as estimated from data 
given i n Refs. [36, 75]. A more specific example is given in 
Fig. 3, which clearly shows the marked change i n the asso­
ciation rate constant k o n and in the dissociation equi l ibr ium 
constant Kj wi th increasing p H for the aprot inin-
chymotrypsin system [76]. 
4. Molecular mechanism of inhibition 
4.1. Formation and structure of aprotinin-proteinase 
complexes 
Our knowledge about the motive forces responsible for the 
formation of a firm complex of a proteinase and a protein-
type inhibitor is based chiefly on the results o f X-ray crystal­
lography studies [82-88] as well as N M R (section 6.2.) [89], 
circular dichroism [90], and kinetic studies [36, 37, 75-80] . 
Complex formation is generally associated w i t h : (1) A per­
fect fit of the reactive-site inhibitor residue (a lysine or argin-
ine residue in the case of trypsin, plasmin and kall ikrein) in 
the specificity pocket of the enzyme; (2) formation o f a 
tetrahedrally oriented intermediate product by action o f the 
nucleophilic oxygen of the alcohol group o f the enzymatic 
active-site serine residue upon the carbonyl group of the ly­
sine or arginine residue of the reactive peptide bond o f the 
inhibitor; and (3) stabilization of the adduct by additional 
reactions in the vicinity of the specificity pocket and reac­
tive-site bond residues, respectively. 
The extended contact area existing between the two poly­
peptide segments of the inhibitor (Posns. 12-18 and 34-39) 
and the various peptide segments of trypsin (Posns. 39-42 , 
57-60, 96-99, 151, 175, 189-195, 214-216; cf. [83, 84]) is 
shown schematically in Fig. 4 and, in greater detail for the 
aprotinin molecule, in Fig. 2. Remarkably, 14 out o f 58 
amino acid residues in aprotinin, i.e. 24% of the total num­
ber of residues in the molecule, and 24 out o f the 224 resi­
dues o f trypsin (i.e. 10.7%) are tightly packed in a density 
comparable to that found in the interior of globular protein 
regions [91]. Consequently, numerous contacts (12 hydrogen 
bonds, a salt bridge, more than 200 van der Waals inter­
actions, and 8 intermolecular water molecules [83, 84, 92]) 
contribute to the appreciable gain in free energy, the driving 
force for complex formation, so that an extremely high free 
energy of association of about 18 kcal/mol and an associa­
tion constant K a ( K a = 1/Kj) of 1.6 χ 10 1 3 1/mol result [36]. 
This high yield of free energy in the complexation is possible 
because the reactive inhibitor domain o f unbound aprotinin 
already has a structure that almost perfectly complements 
the contact region at the surface of trypsin so that only a 
minimal adaptation of the two molecules is necessary [87]. 
This is the principal difference from the reaction of an en­
zyme with a normal substrate chain in which many degrees 
of freedom need to be immobilized to permit optimal inter­
action with the catalytic site of the enzyme. 
Enzyme-catalyzed peptide bond hydrolysis involves forma­
tion o f an acyl-enzyme intermediate (III) via a covalent 
tetrahedral adduct (II) before the hydrolysis can be complet­
ed wi th the aid of a water molecule (IV) (see Scheme 1 [87, 
93]). The reaction is initiated by action of the nucleophilic 
oxygen atom of the enzyme's serine residue on the carbonyl 
carbon atom of the scissile peptide bond (I) as soon as the 
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Figg. 4: Schematic representation of the numerous contacts formed in a pro-
teinnase-aprotinin complex between the amino acid residues of the inhibitor 
(appprox. 24% of all residues) and the enzyme (approx. 11% of all residues). 
Thne key area of the inhibitor fits nearly perfectly into the lock area of the en-
zynme. Painted by A. Hermann according to a space filling α-carbon plot cal­
culated by W. Bode and R. Huber. The X-ray structure of porcine pancreatic 
kalillikrein and its complex with aprotinin has been elucidated very recently, 
see- Bode, W., Chen, Z., Adv. Expt. Med. Biol. (Kinins-III. Part A) 156, 289 
(19983). 
subbstrate is exactly aligned towards the catalytic residues. In 
thee case o f the aprotinin-enzyme complex, the peptide car-
bo^nyl carbon (medium-faced, Scheme 1) is only turned in 
thee direction of the tetrahedral configuration; in other 
wcords, in the stable complex, an intermediate state between 
thee ini t ia l Michaelis-Menten complex (not shown in Scheme 
1)) and the tetrahedral transition state is frozen, presumably 
o w i n g to the optimal fit which this conformation offers both 
prcoteins without any large expenditure of energy [87]. Clea-
yagge of the scissile bond is then hindered by the tight pack-
ingg of the catalytic residues, especially His-57, so that 
I 
traansfer of the proton from His-57 to HN-Ala-16 of the leav-
ingg group, a necessary step for acyl-enzyme formation (see I I 
amd I I I in Scheme 1), is prevented. Although complex for­
m a t i o n is attended by slight distortions in the inhibitor bind­
i n g segments, the reactive-site peptide bond of aprotinin re­
m a i n s intact, therefore. This recently developed concept [87, 
921] provides a rational explanation for the low dissociation 
rattes of most of the aprotinin-proteinase complexes (see sec-
tioon 3.3.). 
In view of the gain in free energy resulting from the numer­
o u s contacts between enzyme and inhibitor i t is not surpris­
i n g that, contrary to previous assumptions, complex forma-
tioDn need not always be preceded by formation of a tetra-
hecdral or acyl-enzyme intermediate. In fact, the enzymati-
callly inactive anhydrotrypsin likewise forms a tight complex 
w i u h aprotinin (Table 2). The structural geometry of this 
/ 
o = c + 
\ 
HN 
R ' 
Τ 
Enzym 
ΗΝ — Η Ν ΝΗ 
O r = C + 
\ 
ΗΟ 
111 
His-57 
Schheme 1: Enzyme-catalyzed peptide bond (I) hydrolysis involves formation 
of aan acyl-enzyme intermediate (III) via a covalent tetrahedral adduct (II) De­
force hydrolysis proceeds to completion with the aid of a water molecule (IV). 
Moodified according to Blow [93] and Huber and Bode [87]. 
complex is very similar to that of the trypsin-aprotinin com­
plex [86]. The same is true of the aprotinin-trypsinogen 
complex [88]. I t appears that enough energy is gained during 
contact of the complementary regions to force the disor­
dered, enzymatically inactive conformation of trypsinogen 
into the ordered high-energy state of the active enzyme [90]. 
Most remarkably, this complex is able to catalyze resynthe-
tis o f modified (reactive-site peptide bond hydrolyzed) 
aprotinin [94]. 
The relatively low affinity of aprotinin for chymotrypsin as 
compared with trypsin (Table 2) is mainly a reflection of the 
poor fit of the inhibitor Lys-15 residue in the specificity 
pocket of this enzyme [82]. The strong interaction o f this re­
sidue wi th the specificity pocket o f trypsin, especially be­
tween the Lys-15 ammonium group and the carboxylate 
group of Asp-189 at the base o f the pocket, contributes 
appreciably to the free energy that is gained during forma­
tion of the aprotinin-trypsin complex [83, 84, 87]. 
4.2. Analogs of aprotinin formed by enzymatic and chemical 
modification 
There is now general agreement that aprotinin is a single-
headed inhibitor having the Lys-15 residue in its active 
center. The location of the reactive-site bond wi th in the se­
quence is generally demonstrated: (1) By l imited proteolysis 
in a slightly acidic solution, which results in an equil ibrium 
between the modified (hydrolyzed reactive peptide bond) 
and virgin inhibitor (reactive peptide bond intact); and (2) 
by resynthesis of the virgin inhibi tor from the modified inhi ­
bitor under appropriate conditions [73, 75, 95]. In the case 
of aprotinin, however, l imited proteolysis of the Lys-15-
Ala-16 bond by bovine trypsin could originally be effected 
only after selective reduction of the disulfide bridge Cys-14-
Cys-38 [96, 97]. After reoxidation, the modified inhibi tor 
could be reconverted to virgin aprotinin by means of trypsin, 
or-chymotrypsin, plasmin or pancreatic kall ikrein, and the 
localization o f the reactive peptide bond could thus be de­
monstrated also by the conventional route [96]. 
It has been shown in the meantime that catalytic amounts o f 
trypsin, chymotrypsin or plasmin establish a true thermo­
dynamic equilibrium between virgin and modified aprotinin 
[80]. The modification reaction proceeds very slowly, how­
ever. W i t h plasmin, for example, the equil ibrium concentra­
tion between virgin and modified aprotinin is reached, under 
optimal conditions, after 300 days, starting from either the 
virgin or the modified inhibitor. In the cases of trypsin and 
chymotrypsin the reaction is even slower. This also shows, 
however, that aprotinin essentially reacts like other protein­
ase inhibitor proteins [73]: its reactive-site bond Lys-15-
Ala-16 is hydrolyzed by catalytic amounts of proteinases, 
and the hydrolyzed bond is subject to thermodynamically 
controlled resynthesis [80]. 
Trypsin 1 from the starfish Dermasterias imbricata was re­
cently found to provide easy access to modified aprotinin 
[74, 79]. In contrast to starfish trypsin 2 which, i n common 
with bovine trypsin, forms a very long-lived complex wi th 
aprotinin, starfish trypsin 1 splits aprotinin rapidly and wi th 
high specificity at the reactive-site Lys-15-Ala-16 bond. A l ­
though starfish trypsin 1 also forms a relatively tight com­
plex wi th aprotinin (Kj - 1 χ 10-9 mol/1), this complex dis­
sociates much more quickly (t. / 2 = 11 s) than the bovine t ryp­
sin-aprotinin complex (t./2 = 107 s). The rates of reactive pep­
tide bond hydrolysis show a similar difference: starfish t ryp­
sin 1 splits the Lys-15-Ala-16 bond a mi l l i on times faster 
than does bovine trypsin [79]. 
The modified inhibitor wi th the hydrolyzed Lys-15-Ala-16 
bond was used to replace the Lys-15 residue wi th other 
amino acids [96, 98]. As expected, replacement of Lys-15 by 
arginine did not affect the inhibitory properties o f aprotinin, 
whereas enzymatic replacement of this basic residue by 
phenylalanine or tryptophan produced a significant increase 
in affinity for chymotrypsin and a decrease in affinity for 
trypsin. O f the various aprotinin derivatives (modified also 
at the y3/y-carboxyl groups o f the aspartic and glutamic acid 
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Table 4: Reactive site residues of structurally related trypsin-chymotrypsin inhibitors of the aprotinin (Kunitz) type. ++, strong inhibition (Kj ^ IO"8 mol/l); 
+, weaker inhibition (Ki > io~8 mol / l ) ; - , no inhibition; 0 , not tested (known); ITI , inter-a-trypsin inhibitor. 
Inhibitor source 
Position of residues Inhibition of 
Reference 
P3 P2 P, Ρί p; p; p; ρ; Ρ» P24 Plasmin 
Kallikrein of 
Tissue Plasma 
Bovine organs: 13 14 15 16 17 18 19a) 203) 38 39 
aprotinin Pro CYS Lys - Ala Arg He He Arg CYS Arg ++ ++ + [17, 18] 
Sea anemones, 5 I I Pro CYS A r g - Ala Arg Phe Pro Arg CYS Arg ++ ++ + [102] 
Snails, Κ Pro CYS Lys- Ala Ser Phe Arg Gin CYS Arg ++ + 0 [103] 
Bovine serum, BI-8 Pro CYS Lys - Ala Ala Met He Arg CYS Arg ++ + + [12] 
RussePs viper, II Arg CYS A r g - Gly His Leu Arg Arg CYS Gly + e) + e) + e) [104] 
Cobra, Ν NY I I b ) Leu CYS Lys - Ala Arg He Arg Ser CYS Gly 0 ++ 0 [42, 105] 
Cobra, HHV IF) Leu CYS Lys - Ala Tyr He Arg Ser CYS Gly + + e ) ++ 0 [42, 105] 
Cow colostrum Pro CYS Lys - Ala Ala Leu Leu Arg CYS Gin ++ - - [106] Human ITI-14-2 Pro CYS A r g - Ala Phe lie Gin Leu CYS Gin 
+
r > - f ) 0 [Π] 
Bovine ITI-14-2 Pro CYS A r g - Ala Phe He 0 0 CYS Lys 0 [12] 
Soybean, Kunitz d) Ser Tyr A r g - lie Arg Phe He Ala ++ - ++ [107] 
f) Not involved in the contact with trypsin in the complex. 
b ) Naja nivea venom. 
c ) Hemachatus haemachatus venom. 
d ) Not structurally related. 
Ρ Estimated from titration curves or author's classification (no quantitative data available, see references). 
r ) Hochstrasser, K., unpublished data (1981). 
residues) described recently [99], those wi th a hydrophobic 
amino acid residue in position 15 are interesting inasmuch 
as they show high affinity for human granulocytic elastase 
[100]. It is noteworthy that substitution of Lys-15 by 
glycine did not entail a significant decrease i n the affinity of 
aprotinin for porcine pancreatic kall ikrein [100]. 
The recently accomplished total synthesis of aprotinin opens 
the way to a detailed study o f the effect o f amino acid ex­
changes on the inhibi tory properties of this molecule [101]. 
The results of studies on the synthesis of aprotinin, aprotinin 
analogs, and polypeptide models o f the reactive center o f 
aprotinin have lately been reviewed [7], 
4.3. The structural basis of kallikrein inhibition 
While the tertiary structure o f the active site o f the ka l l i -
kreins remains unknown 3 ), insight into the structural basis 
for kal l ikrein inhibi t ion by aprotinin can be gained only by 
comparison with the inhibi tory specificities and reactive-site 
sequences of structurally homologous inhibitors (Table 4). 
Crystallographic studies have revealed that the amino acid 
residues of aprotinin that are in most intimate contact w i th 
trypsin in the complex comprise, i n addition to Cys-14 and 
Cys-38, the "specificity pocket" residue Lys-15, Ala-16, and 
the basic residues Arg-17 and Arg-39 (Fig. 2) [83, 84]. In 
view of the inhibitory specificities of structurally homolo­
gous inhibitors i t is evident that the relatively strong reac­
t ion o f aprotinin wi th the kallikreins is due to the basic char­
acter of the residues i n positions 17 and 39 [108]. 
Replacement of both basic amino acid residues in these 
positions by neutral residues completely abolishes the affin­
i ty o f an aprotinin-type inhibi tor for both tissue and plasma 
kallikreins (cf. cow colostrum inhibitor) . If, however, a basic 
residue is present i n position 19 (cobra H H V II) , kal l ikrein-
inhibi t ing activity is displayed. It appears, then, that in an 
aprotinin-type inhibi tor a basic amino acid residue is re­
quired in one or more o f these positions - 17, 19, 39 - to 
produce enough energy for complex formation wi th ka l l i ­
krein. 
This hypothesis is supported by recent studies o f the struc­
ture/function relation in an aprotinin-type inhibi tor from 
bovine serum [12] and o f the trypsin-inhibiting aprotinin-
type domains (ITI-14-2) derived from human and bovine 
inter-tf-trypsin inhibi tor [11, 12] (Table 4). The inhibi tor 
3 ) The X-ray structure of porcine pancreatic kallikrein and its com­
plex with aprotinin has been elucidated recently, see: Bode, W., 
Chen, Z., Adv. Expt. Med. Biol. (Kinins-III, part A) 156, 289 
(1983). 
from bovine serum bearing arginine in position 39 is a fairly 
potent inhibitor of tissue kallikrein, whereas the inhibi tory 
domain ITI-14-2 of the human inter-a-trypsin inhibitor 
has no basic residue in any of the above-cited positions and 
so fails to inhibit tissue kallikrein. The ITI-14-2 domain de­
rived from the bovine inter-#-trypsin inhibi tor , on the other 
hand, bears a basic residue in position 39, lysine, but does 
not inhibit tissue kallikrein, either (Table 4). In the latter 
case, however, a large residue (e.g. tryptophan) in position 
19 may prove a steric hindrance to complex formation. 
The affinity of an aprotinin-type inhib i tor for plasmin (or 
trypsin), as contrasted with kallikrein, is not significantly af­
fected by such replacements of amino acids at the reactive 
site. The inhibit ion of plasma kall ikrein and, notably, tissue 
kallikrein evidently requires additional structural features in 
specific subsite positions. This is true because of the more 
restricted substrate specificity of the kallikreins as compared 
with trypsin or plasmin. We may justifiably infer that the 
active sites of any of the kallikreins that form complexes 
with aprotinin are very similar. A close similari ty between 
porcine and human tissue kallikrein or urinary kallikrein 
has in fact been reported recently [44]. Yet the decidedly 
lower affinity between aprotinin and the kallikreins when 
compared with trypsin (Table 2) indicates that the fit o f the 
complementary contact regions in the aprotinin-kallikrein 
complex is less than perfect, or that the contact area differs 
markedly from that of the aprotinin-trypsin complex. This is 
true at least for contact in the specificity pocket - replace­
ment of Lys-15 by glycine did not significantly affect the af­
finity of aprotinin for tissue kallikrein [100]. 
Kallikrein inhibitors as well as kallikreins are known to oc­
cur in snake venoms [104, 105]. Furthermore, snake toxins 
may be structurally related to aprotinin without possessing 
inhibitory activity against known proteinases [109]. The sig­
nificance of these observations is as yet unclear. 
5. Special properties relevant to administration of aprotinin 
5.1. Interaction with glycoproteins and mucopolysaccharides 
The relatively high basicity of aprotinin, which is due to its 
high isoelectric point of 10.5 [21], seems to be chiefly re­
sponsible for two special features of this inhibitor molecule: 
(1) Its binding to acidic glycoproteins or mucopolysacchar­
ides including heparin [110, 111], and (2) its " f ixa t ion" and 
degradation in the kidney following therapeutic administra­
tion [112-114]. Aprot in in derivatives o f lower basicity [96, 
112] and aprotinin-type inhibitors from sea anemones [115] 
and snails [96, 116] as well as other trypsin inhibitors o f si-
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mil ia r molecular weight but lower basicity [112] are excreted 
in tthe urine. 
5.22. Immunogenicity 
ApDrotinin-specific antibodies have not so far been observed 
in human sera during or after aprotinin treatment [117]. 
Ap^rot inin thus appears to be a comparatively weak i m -
miunogen. 
Guainea pigs can, however, be sensitized to i t by a special i m -
m ionizat ion program [117]. Aprotinin-precipitating antisera 
hawe also been obtained in rabbits by immunization wi th 
cormplete and incomplete Freund's adjuvant. These antisera 
wetre identified by immunodiffusion and immunoelectro-
phcoresis (Eben, A . and Truscheit, E., 1964; data published 
by Haberland [117]). Other immunization methods for 
aprrotinin were described recently [10, 13, 14]. Aprot in in-
speecific antibodies were also obtained when high-molecular 
weiight cross-linked aprotinin served as the immunogen 
[1118]. 
Ap^rotinin-specific antisera produced according to Eben and 
Trvuscheit [117] have been used in immunofluorescence stu-
diess [114] and in radioimmunoassays [35, 114]. These anti-
serra were found capable of neutralizing almost completely 
the? trypsin-inhibit ing activity of aprotinin when gelatin 
[1118], casein or BzArgOEt (Truscheit, E., unpublished ob-
servation) was used as substrate. 
5.3k Elimination after administration 
Serrum or plasma levels o f aprotinin obtained after i.v. injec-
tiorn in animals and humans decline rather rapidly owing to 
disttribution of the inhibi tor in the extracellular fluid and 
subsequent accumulation, particularly in the kidney [7, 
1199-121]. The following human serum levels were meas-
ureed, for example, per Mi l l i l i t e r after i.v. administration of 
a siingle bolus o f 500,000 or 50,000 K I U [121]: 0.25 h: 50, 
5; (0.5 h : 35, 3.5; 1 h : 25, 2.5; 2 h : 17, 1.7; 4 h : 10, 1. The 
hallf-life o f elimination changed from approximately h/2 = 
0.7? h 1 h after injection to t>/2 = 7 h 12 h after injection. 
Aboout 80% of the aprotinin dose is found in the rat kidneys 
afteer 4 h [119]; aprotinin is taken up by the epithelial cells 
of tthe proximal tubules [113, 120]. It appears that aprotinin 
is ailmost entirely metabolized in the kidney lysosomes [120] 
inaäsmuch as biologically active aprotinin is not normally ex-
cretted in the urine. Only 1.5% of 1,000,000 K I U , for exam-
ple;, was found in human urine a short time (1.5 h) after i.v. 
injeection [119]. Apro t in in that is covalently bound to solu-
ble- polysaccharides is more slowly eliminated from the cir-
cu la t ion and is excreted wi th the urine without accumulating 
in tthe renal tissue [122]. 
Altthough the toxicity o f aprotinin is extremely low - the 
L D ) 5 0 for mice and rats is 2.5 χ 106 K I U / k g and that for rab-
bitss 0.5 χ 10 6 K I U / k g - rapid i.v. injection of large doses 
shou ld be avoided, for the high basicity of aprotinin may 
cauase liberation of histamine and lead to an anaphylactoid 
reatction. 
5.4k Effects on cellular function 
In wiew of the widespread use of aprotinin as a proteinase in -
hibii tor, recent observations of additional biological effects of 
thiss inhibitory polypeptide merit special attention. Apro t i -
n i m has been found to influence the response of body cells 
suchh as leukocytes, platelets, and macrophages to various 
st imiul i as well as the activities of membrane-associated en-
zyimes. We know little, however, about the mechanisms of 
thesse actions of aprotinin. These effects are briefly discussed 
in ssection 6.5. 
6. EBiochemical and biomedical applications 
6.1.. General applications 
Apirot in in has proved to be a valuable tool in biochemical 
andi biomedical research and in routine procedures used in 
thesse areas. It is used extensively for the following purposes: 
6.1.. 1. Proteinases inhibited by aprotinin can easily be puri­
fied! by affinity chromatography with insolubilized aprotinin 
derrivatives [7], e.g. aprotinin-Sepharose [123] and aprotinin-
cellulose [15]. Besides trypsin [123-125], chymotrypsin. 
[123], pancreatic elastase [52], and plasmin or plasmin frag­
ments [126, 127], plasma and tissue kallikreins [7, 44, 1.28, 
132], as well as granulocytic elastase and cathepsin G [133, 
134] have been successfully isolated by this means under ap­
propriate conditions. Aprotinin-Sepharose has also been 
used for purification of a hormone-degrading enzyme [135]. 
6.1.2. Aprotinin-sensitive enzymes can be crystallized as 
aprotinin-proteinase complexes either for purposes o f pur i f i ­
cation [2] or for X-ray crystallography [82-84]. For the lat­
ter purpose, complexes o f aprotinin with inactive enzymes 
such as anhydrotrypsin [86] and trypsinogen [88] have been 
crystallized as well. 
6.1.3. Apro t in in is widely used as a molecular weight 
marker (M.W. approx. 6500) in gel permeation chromato­
graphy [136] and SDS electrophoresis [137] (see e.g. Product 
Profile 6040SA from Bethesda Research Lab., Rockville, 
USA) . 
6.1.4. Kal l ikre in activity i n a mixture of esterases and pro­
teinases can be identified by specific inhibi t ion of the ka l l i ­
krein wi th aprotinin. Thus, the presence of aprotinin (10 
K I U / m l , i.e. 2 χ 10-7 mol/1) in the assay k i t for determina­
tion o f kall ikrein activity in human urine by use of a syn­
thetic substrate permits a clear distinction to be made be­
tween substrate cleavage induced by kall ikrein and by uro­
kinase [138]. 
6.1.5. Apro t in in is frequently used to solve a common prob­
lem in biochemical and biomedical research: how to prevent 
proteolytic degradation of proteins or polypeptides, en­
zymes, proenzymes, preproteins, etc. in biological fluids or 
tissue extracts and during purification. Apro t in in is used for 
the following purposes, for example: (a) Suppression of 
proenzyme activation during purification o f kininogens 
[139, 141], and preparation and assay of plasma samples 
used for determination of fibrinopeptide A or Β [142]; (b) 
prevention of breakdown of Proteohormones such as gluca­
gon during the preparation and assay of samples to be used 
in radioimmunoassays [143-146]; (c) preservation of pro-
tease-sensitive plasma factors such as clotting factor V I I I 
(antihemophilic factor) [147] and fibronectin [148] during 
their isolation, storage and analysis. Apro t in in concentra­
tions used for these purposes ranged from 100 K I U / m l (i.e. 
approx. 2 χ 1 0 6 mol/1) to 1600 K I U / m l (i.e. approx. 3x10-5 
mol/1); in most cases 500 K I U / m l (approx. 1 χ 10-5 mol/1) 
should be sufficient. 
6.1.6. Apro t in in may be used to terminate lysis caused by 
proteinases in tissue culture studies (see section 6.3.) and i n 
experiments in which only a l imited proteolysis is required. 
Examples are inhibi t ion o f kinin-liberating enzymes in sam­
ples subjected to biological assays (by 1650 K I U / m l ) [149], 
and preparation of defined molecular forms o f plasmin [150, 
151]. 
6.2. Tool for protein conformation and protein-protein 
interaction studies 
Apro t in in , a typical globular protein, has been used in nu­
merous studies on the fundamental aspects o f protein con­
formation [22, 152-155]. These have included theoretical 
and experimental studies o f the internal mobi l i ty of proteins, 
protein folding, and surface interactions wi th solvents, and 
they have led to a novel description o f globular protein con­
formation by a dynamic grouping of rapidly interconverting 
molecular structures [22, 152, 153]. I t is especially interest­
ing that the average solution conformation of aprotinin 
closely matches the conformation of its crystalline structure: 
"Hydrophobic clusters form stability domains" in the inter­
ior o f the inhibi tor "which function as pillars for the archi­
tecture of the protein molecule" [153]. In these studies, 
furthermore, nuclear magnetic resonance was used wi th ad­
vantage for the conformational description o f aprotinin ana­
logs adapted to mechanistic studies of proteinase-inhibitor 
interactions [156] and to studies of the state o f catalytic 
groups in proteinases, proenzymes, proteinase inhibitors and 
their complexes [157, 158]. Extensive knowledge o f the pro-
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perties of aprotinin also permits its application to the solu­
tion o f as yet unsolved problems, such as e.g. a molecular 
explanation for the dramatic differences in the dissociation 
rates of the complexes of aprotinin wi th either bovine tryp­
sin or crayfish trypsin 1 despite the excellent affinity for 
aprotinin shown by both enzymes (see section 3.3.) [74, 79]. 
The significance of aprotinin ("E. Werle's kallikrein i n -
activator") as a model compound in biochemistry and bio­
physics has been further outlined recently by Huber, R., 
Adv. Expt. Med. Biol . (Kin ins - I I I , Part A) 156, 29 (1983). 
6.3. Tissue culture and organ preservation 
When present in cell culture media in concentrations rang­
ing from 300 K I U / m l (approx. 6x10 -6 mol / l ) to 10,000 
K I U / m l (approx. 2 χ 1 0 4 mol / l ) , aprotinin exerts a variety 
of effects: 
(1) I t delays the degradation o f Proteohormones such as sub­
stance Ρ [159] and insulin [160, 161]. Prevention o f insulin 
degradation by aprotinin accounts for the observed increase 
in the absorption of subcutaneously injected insulin i n the 
presence of the proteinase inhibi tor [162]. Aprot in in may 
thus be successfully used to treat insulin-resistant diabetes 
[163]. 
(2) It preserves the integrity and so extends the lifes o f cells 
and cell membranes from kidney [164] and cerebellum 
[165]. 
(3) A dose-dependent inhibi t ion of D N A , R N A and protein 
synthesis has been observed in stimulated mous lymphocytes 
at aprotinin concentrations between 0.3 χ 10-7 and 2.5 χ 10-7 
m o l / l [166]. 
(4) I f applied in relatively small amounts (10 to 500 
K I U / m l ) , i t prevents toxic products released from disinte­
grating cells from damaging intact targets [167]. 
(5) It inhibits the uptake of adenosine by cardiac cells; this 
can be important for improved perfusion of the myocar­
d ium in vivo [168]. 
Apro t in in has also been reported to have an advantageous 
effect on organ preservation. For kidney preservation, 
aprotinin (500-2000 K I U / k g body weight) was injected into 
animals immediately before removal of the organ, which 
was then incubated in an aprotinin-containing medium prior 
to transplantation [169, 170]. A protective effect of aprotinin 
on lung tissue in vi tro has also been described recently [171]. 
6.4. Inhibition of (transformed) cell growth 
Several groups have investigated the possible usefulness of 
aprotinin as an immunotherapeutic agent in cancer. It was 
found to inhibi t the growth o f malignant transformed cells 
(at lower doses) but also the growth of normal cells (at 
higher doses), aprotinin being bound and endocytosed by the 
tumor targets [172, 173]. Apro t in in administered by various 
routes depressed the growth and invasiveness o f solid tumors 
i n animals [174]. Recent studies indicate that this therapeu­
tic effect o f aprotinin may be mediated by improvement in 
the host's immune response to tumors [175]. It was noted, 
for example, that bolus injection o f a high dose of aprotinin 
i n both human subjects and animals led to a significant i m ­
provement of the in-vi t ro lymphocyte response, and this in 
tu rn resulted in reduction of the tumor-induced lymphocyte 
suppression [175]. Apro t in in is apparently able to improve 
cell-mediated immuni ty by direct action on the lymphocyte 
(see section 6.5.), and the effect is stronger in cancer patients 
than i n normal subjects. However, not all studies have con­
firmed that aprotinin can inhibi t tumor growth and invasive­
ness. The conflicting results reported by different authors 
may be due to a dose and species dependence of the effect. 
6.5. Effects on leukocytes and macrophages 
Apro t in in affects various enzyme systems of the leukocytes 
and the response o f lymphocytes. It inhibits, though rather 
weakly, a basophil kall ikrein-like enzyme that is released 
(together wi th histamine) from human peripheral leukocytes 
upon stimulation wi th IgE [176, 177]. By means of aproti-
nin-Sepharose, leukocytic proteinases generating factors 
from complement C5 that are chemotactic for leukocytes 
and tumor cells can be removed from the incubation me­
dium [178]. With the use of this affinity sorbent, a k a l l i ­
krein-like enzyme was recently isolated from the cytosol o f 
polymorphonuclear granulocytes [179]. This enzyme seenns 
to be different from the kininogenase that is believed to be 
present in the lysosomal lysate o f the same cells [180]. 
Aprot in in can either increase (at low doses) or inh ib i t (at 
higher doses) the response of peripheral lymphocytes to va r i ­
ous stimuli but it is toxic to unstimulated cells i n culture 
[181, 182]. Remarkably, it binds to the plasma membrane of 
both peripheral blood lymphocytes and polymorphonuclear 
leukocytes [181]. Endocytosis o f aprotinin was demonstrable 
in the latter case. It is therefore conceivable that apro t in in 
influences cell function by inhibit ing ( in secondary lyso-
somes) neutral proteinases that are normally released extra-
cellularly to potentiate lymphocyte stimulation. 
Leukocytic cathepsin D releases sizable amounts o f leukoki -
nins, i.e. potent permeability agents, from a precursory pro­
tein, leukokininogen, which is found in ascites f lu id pro­
duced in neoplastic diseases [183]. Cathepsin D can act 
upon this substrate only after conversion o f a prosubstrate to 
leukokininogen, a process mediated by a trypsin-like en­
zyme. This proteinase, too, is effectively inhibited by aproti­
nin [184]. 
During macrophage-tumor interaction, aprotinin can inhibi t 
the cytolysis of the neoplastic targets by activated macro­
phages i f present in a concentration of 750 K I U / m l (approx. 
1.5 χ 10-5 mol/ l ) [185]. The cytolytic activity was found to 
be generated by a specific proteinase that is secreted by the 
activated macrophages [186]. 
6.6. Blood preservation and inhibition of platelet aggregation 
Platelet aggregation (the second phase, associated wi th re­
lease of serotonin) is very effectively inhibited by aprotinin 
concentrations between 0.4 χ 10-5 and 1 χ 10-5 m o l / l 
[187-191]. The spontaneous formation of microaggregates 
in stored blood is thus prevented, clotting factors are pro­
tected, and fibrinolytic activity is depressed, at least for 5 
days. Under transfusion conditions, platelet function is 
immediately restored so that the patient's coagulation status 
remains unchanged [187, 189]. Furthermore, a bolus injec­
tion of 20,000 K I U / k g body weight of aprotinin can lessen 
the tendency to aggregation ordinarily observed after major 
surgery [192]. 
6.7. Wound healing 
It has been reported that aprotinin reduces the development 
of adhesions and of secondary necrosis after operations [193, 
194]. The inhibitor is also used as an additive to adhesive 
fibrin ("fibrin glue") for adapting tissues and sealing bleed­
ing areas with fibrin, preventing its dissolution before tissue 
repair has set in [195-197]. 
6.8. Tool for studies of muscle metabolism and renal 
function 
Glucose uptake by working human muscle cells is signif­
icantly reduced after aprotinin administration (bolus injec­
tion of 500,000 KIU/10 min) but returns to normal upon 
concomitant administration of bradykinin (13 ng/min) 
[198-200]. High doses of aprotinin (125,000 K I U / k g i.v.) 
also delayed appreciably the metabolic rehabilitation o f rat 
skeletal muscle during recirculation following ischemia 
[201]. A rational explanation for these observations is the in­
volvement of kallikrein or a kallikrein-like enzyme in the 
mediation of insulin action on glucose uptake by skeletal 
muscle by way of kinin liberation [200]. 
The administration of aprotinin to volume-expanded rats 
leads to a significant reduction of glomerular filtration rate, 
clearance, urine volume, and urinary immunoreactive PGE 2 
[202]. This finding suggests that the kall ikrein-kinin system 
may contribute to changes in renal function during extracel­
lular volume expansion. Apro t in in is therefore a valuable 
tool in studies on the involvement of the kallikrein-kinin 
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sysstem i n the body's regulatory mechanisms. Besides kal l i -
krceins a n d kininogenases, however, other enzyme systems 
maay be affected by aprotinin. A n example is the human kid­
n e y aminiopeptidase of the brush border membrane. This en-
zyrme is activated by aprotinin in its membrane-bound form 
bui t inhabited by i t after solubilization [203]. 
6.S9. Effects on fertilization 
Proteases p l a y a significant role in the fertilization process 
[2(04, 205 ] . The trypsin-like acrosomal proteinase acrosin, 
forr example, assists the spermatozoon in penetrating the 
zoma pel lucida of the ovum; trophoblast and uterine protein-
asees a id i n implantat ion of the blastocyst in the uterus. Pro­
teinase inhibi tors could therefore be utilized to prevent con­
ception.. Recent investigations have shown that in-vivo use 
of; ap ro t in in for the blockade of acrosin is difficult because of 
thee high concentration (approx. 1 χ 10-2 mol / l ) that is needed 
i f t t h e i n h i b i t o r is to penetrate the sperm head membranes 
[644]. In rabbits, however, implantation could by prevented 
wi i th miuch lower concentrations o f aprotinin when this was 
inttroduced into the cavum uteri [206]. This contraceptive ef-
fecct o f ap ro t in in may result from inhibit ion of a trypsin-like 
or kal l ikre in- l ike proteinase of the rabbit trophoblast that 
plaays a role i n the ini t iat ion of embryo implantation in the 
uteerus [65] . 
Inifusion o f aprotinin in pregnant rats led to a reduction of 
uteerine m o t i l i t y and a significant prolongation of parturition 
b y comparison wi th saline-infused controls [207]. Aprot in in 
is of benefit in cases of menorrhagia and intramenstrual 
spootting due to the use of intrauterine devices [208]. Repeat­
ed! injections into the uterine cavity stop the bleeding and 
maarkedly reduce inflammatory reactions including pain. 
Prrior intravaginal administration of aprotinin has been re-
po)rted t o preserve the integrity o f cells in vaginal smears 
[2C09]. 
6.110. Experimental shock 
Approtinin has been widely used in experimental studies of 
shcock and shock lung and in the treatment of these condi­
t ions i n humans [210-212]. The underlying rationale stems 
fro)m the finding that kinins and polypeptides are released 
f r o m hypoxic and damaged tissue by the action of protein­
ases including the kallikreins [211-213]. Such peptides can 
inttensify the inflammatory response via several routes and 
maay prove toxic to the heart and lungs [212, 214]. Further, 
apirot inin has been found capable of aborting hyperfibrinoly-
sis; and o f reducing the disseminated intravascular coagula-
t iom which is frequently associated wi th the shock syndrome 
[2113, 215, 216]. While a protective effect of aprotinin on an-
imials i n experimental shock has been observed in most of 
thee studies, a beneficial effect o f aprotinin treatment was not 
seen in other studies [217, 218]. That conflicting results 
shcouid have been obtained is not surprising considering the 
differences in experimental approach and the varying aproti-
n im doses used by different workers. There is growing evi­
dence f rom both experimental and clinical studies that the 
theerapeutic effectiveness is dependend on administration of a 
h i g h dosage of aprotinin in an early phase of the disease as 
shcown e.g. convincingly for bile-trypsin induced pancreatitis 
in (dogs [219]. 
Recently refined techniques have made it possible to study 
in greater detail the mechanism of trypsin inhibition by se-
rurm inhibitors and additionally injected aprotinin in dogs 
witth trypsin-induced shock [220]. In the absence of aproti-
nim administration, infusion of trypsin led to irreversible 
shcock as soon as the or-macroglobulins were saturated, while 
frete <X\-antitrypsin was still present in excess. The drop in 
blox)d pressure was correlated wi th kininogen consumption, 
refTlecting the release of highly vasoactive kinins [221]. In the 
presence o f aprotinin, however, trypsin infusion could be 
comtinued beyond saturation o f the alpha-macroglobulins 
witthout causing irreversible hypotension or significant k in -
hxDgen consumption [220, 221]. Evidently, aprotinin, unlike 
a , -ant i t rypsin, can protect the animal against the irreversi-
ble? shock that is produced in control animals after consump­
t ion o f the <z-macroglobulins. Aprotinin-trypsin complexes 
and tf-macroglobulin-trypsin-aprotinin complexes were in 
fact demonstrable in the aprotinin-treated animals. Appar­
ently, trypsin is even transferred from the trypsin-ai-
antitrypsin complex to free aprotinin. 
These studies have made it clear that a powerful exogenous 
proteinase inhibitor can, at the very least, delay serious cl in­
ical complications when the inhibi tor reserve of the body i t ­
self has been exhausted. That this can occur under patholo­
gical conditions has been shown in experiments concerned 
w i t h pathobiochemical processes secondary to experimental 
induction of pancreatitis in dogs [222]. Besides a consider­
able increase of trypsinogen levels in the circulation, a\-
antitrypsin-trypsin complexes were detected. Such com­
plexes can cause irreversible hypotension when infused into 
dogs depleted of a-macroglobulins that have not been treat­
ed wi th aprotinin [220]. Remarkably, the distribution o f 
trypsin between # 2-macroglobulin, aprotinin and oc\-
antitrypsin in human serum samples in vitro [223] is similar 
to that found in dog plasma specimens following trypsin-
induced shock. 
6.11. Effect on virus replication and bacterial growth 
According to evidence presented recently, virus replication 
is regulated by cell-specific proteases [224, 225]. Proteinase 
inhibitors should consequently be able to interfere wi th virus 
replication and infectiosity. Apro t in in has in fact been 
shown to increase the survival rate in swine fever disease 
[226]. This disease is linked to the formation of a chymo-
trypsin-like proteinase by the virus-infected cells [227]. It is 
possible that aprotinin affects this disease by inhibit ing such 
a virus-associated proteinase. Inhibi t ion of bacterial growth 
by aprotinin has also been reported [228]. In these studies 
aprotinin proved to be effective both in in vitro conditions 
and in vivo. 
7. Clinical use 
7.1. General aspects 
Indications for therapeutic or prophylactic use of aprotinin 
have been studied intensively. Apro t in in administration is 
recommended e.g. as part of the therapeutic regimen in 
acute pancreatitis, various states of shock syndroms, and hy-
perfibrinolytic hemorrhage [229-236]. However, the at­
tempt to demonstrate clinical effectiveness by prospective 
controlled clinical trials has proved to be extremely difficult 
and has been successful only for some of the suggested ind i ­
cations, despite of sound biochemical rationale. This may be 
largely due to problems in clinical methodology. For acute 
pancreatitis, as an example, several clinical double-blind 
trials yielded conflicting results. The statistically significant 
reduction in mortality observed in one study by Trapnell et 
al. [229] could not be confirmed by others [237, 238], leav­
ing the question unsolved whether aprotinin is effective only 
in special types of the disease. On the other hand, activation 
o f trypsin, chymotrypsin and elastase in acute pancreatitis 
has been demonstrated by detection o f complexes o f these 
enzymes wi th ax-antitrypsin in peritoneal exudates [239] as 
well as i n the circulation [240, 241]. In addition, most o f the 
a 2-macrog.lobulin present in the exudate was found to be 
complexed with proteinases [239]. These findings provide a 
clear biochemical rationale for the therapeutic use o f suit­
able proteinase inhibitors even though the benefit to the pa­
tient may be hard to prove statistically because o f the com­
plexity o f the disease. 
In traumatic-hemorrhagic shock prospective clinical trials 
wi th reference either to mortali ty [236] or post-traumatic 
pulmonary insufficiency [230] have clearly demonstrated 
clinical effectiveness. Patients may be expected to benefit 
most i f aprotinin is given i n an early phase o f this disease 
[236]. 
7.2. Interaction with plasmin and plasma kallikrein 
Among the numerous biological effects o f aprotinin, its i nh i ­
b i t ion o f plasmin and plasma kall ikrein is o f special interest. 
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Scheme 2: Solid-phase activation of the intrinsic coagulation pathway: in­
teractions between clotting, fibrinolysis, complement, and the kin in-gener­
ating system [242, 243]. 
Plasma kallikrein accelerates activation (+, positive feedback), whereas the 
histidine-rich peptide, cleaved off from high-molecular weight (HMW) kinin­
ogen by plasma kallikrein, inhibits activation (-, negative feedback). HMW 
kininogen binds factor X I and plasma prokaliikrein (both occur in plasma 
associated with it) via the histidine-rich peptide to the negatively charged sur­
face, an exposed collagen fiber or basal membrane, lipopolysaccharides, glass, 
kaolin, etc. Aprotinin can inhibit the action of both plasmin and plama kalli­
krein, as indicated by circles in the pathways. 
How these enzymes interact wi th other coagulation factors 
or fibrinolytic factors is shown diagrammatically in Scheme 
2 [242, 243]. 
Since aprotinin has a significantly greater affinity for plas­
m i n (see Table 2), i t should be possible to regulate the de­
sired effect, viz. inhibi t ion o f either fibrinolysis or blood 
clotting, by commensurate dosing o f the inhibi tor [244]. 
This presupposes knowledge of the actual concentrations of 
all the reactants in relation to time, under in-vivo condi­
tions, and these concentrations cannot at present be deter­
mined because o f the lack o f appropriate methods. They 
can, however, be calculated for systems containing only 
plasminogen, plasma prokaliikrein, and aprotinin [245]. In 
this case aprotinin w i l l be bound to liberated plasmin up to 
equimolar concentrations inasmuch as the dissociation con­
stant o f this complex is far below the in-vivo plasmin/plas-
minogen concentration. The in-vivo concentration of plas­
ma prokaliikrein, however, approaches the Kj-value o f the 
aprotinin-kallikrein complex. Therefore, a large molar ex­
cess of aprotinin is needed to obtain complete inhibi t ion of 
liberated plasma kall ikrein. This can be simulated in a test 
system measuring contact activation of the coagulation cas­
cade, which is stimulated by plasma kallikrein. Strong inhi ­
bi t ion is obtained only at aprotinin concentrations ranging 
from 250 to 500 K I U / m l , equivalent to a five to tenfold mo­
lar excess o f aprotinin over plasma prokaliikrein resp. kal­
l ikrein [245, 246]. For complete inhibi t ion o f plasmin in the 
pure system, an aprotinin concentration o f 125 K I U / m l is 
sufficient provided all of the plasminogen is transformed 
into plasmin [245]. Smaller quantities of aprotinin should 
suffice under in-vivo conditions since small amounts only of 
the proenzymes are activated ordinarily and most of the l ib­
erated proteinases are rapidly inhibited and eliminated by 
the natural inhibitors, which are present in molar excess 
over the proenzymes/enzymes [247]. 
It is noteworthy that aprotinin also effectively inhibits - in 
addition to plasmin - the plasmin-streptokinase complex 
which is an intermediate in plasminogen activation during 
thrombolytic therapy with streptokinase [41]. Even though 
the inhibi t ion o f this complex proceeds comparatively slow­
ly (at 1 μπιοΙ/\ aprotinin, the association half-life is 250 s; 
ki = 1.1 χ 10« 1 m o H s-1 and k 2 = 1.1 χ 103 s-1; cf. section 
3.3.), aprotinin may be used to control bleeding complica­
tions following thrombolytic therapy with streptokinase [41]. 
8. Synopsis 
The data and observations we have cited show that we al­
ready have detailed knowledge of the chemical, physical and 
biochemical properties o f aprotinin and its inhibitory mech­
anism of action. Apro t in in is readily available i n pure 
form and is therefore widely used in various research disci­
plines and routine assays. It has also become a valuable drug 
for the treatment o f a variety o f diseases. The i n f o r m a t i o n 
about functional aspects o f aprotinin remains scanty, how­
ever. 
The following aspects are o f special interest for future re­
search: (1) The molecular basis for the pharmacologic effects 
of aprotinin not associated wi th proteinase i n h i b i t i o n , i n ­
cluding its interactions wi th membranes; (2) evaluat ion o f 
optimal dosage for interfering either w i t h the coagulat ion/ 
kinin-liberating or the fibrinolytic pathway in v ivo ; (.3) eval­
uation of optimal dosage for inhibi t ion o f tissue kal l ikre ins 
and/or other proteinases such as trypsins and chymotrypsins 
liberated during local inflammatory processes; (4) the func­
tional significance o f the occurrence o f aprot inin i n the h igh­
ly specialized tissue mast cells throughout the bovine organ­
ism; and (5) the functional significance o f the aprot in in- l ike 
inhibitor that is present i n bovine serum and o f the apro-
tinin-type polypeptide domains in the inter-a-trypsin i n h i b i ­
tor. Elucidation of the last two questions is l ikely to open 
additional avenues of aprotinin research and future medical 
applications. 
9. Appendix on aprotinin applications 
9.1. General comments 
9.1.1. Availability 
Aprotinin is available as a sterile solution in ampoules (Trasyiol®) 
from Bayer and from FBA-Pharmaceuticals. For research purposes 
it may also be obtained in lyophilized form. It is identical with BPTI 
(basic pancreatic trypsin inhibitor), PTI (pancreatic trypsin inhibi­
tor (Kunitz)), kallikrein inhibitor from bovine organs, etc. [21]. 
Aprotinin preparations may contain. ATPase inhibitors [248] but 
the Trasyiol commercially available has been free of this agent for 
several years now (A. Arens, personal communication, 1980). 
9.1.2. Storage 
Aprotinin may be stored in lyophilized form below 4 °C for an "un­
limited" time without losing its inhibitory activity. Aprotinin solu­
tions in salt-buffer media, pH 5-8, are stable at least for one month 
at 4 °C and below -20 °C for years; the same holds true for open am­
poules. During storage in solution, bacterial growth should be pre­
vented by addition of preservatives such as sodium azide, benzyl al­
cohol, pentachlorophenol, thiomersal, and antibiotics. However, a 
possible direct pharmacologic effect of the preservative has to be 
taken into account when biological studies are performed. For 
biochemical assays preservatives need not be added. 
Aprotinin solutions of pH < 4 and > 9 should be used within a few 
hours. Direct exposure of aprotinin solutions to sunlight, UV-light 
and reducing agents should be avoided. 
9.1.3. Dialysis, ultrafiltration and chromatography 
Aprotinin penetrates readily ordinary dialysis tubes but not acetylat-
ed ones. In the absence of a suitable salt concentration (below ap­
prox. 0.1 mol/1 NaCl) it may be bound to negatively charged sur­
faces of cell membranes and solid supports, thus giving rise to 
unspecific effects or loss of aprotinin (e.g. in gel permeation chroma­
tography or ultrafiltration). 
9.1.4. Interaction with heparin 
Under in-vitro conditions heparin may associate with aprotinin, 
causing turbidity or precipitation. This can be avoided by increasing 
the salt concentration of the solution. As a precaution, aprotinin 
should not be used in chromogenic substrate assays in the presence 
of heparin, or mixed with heparin for blood sample collection and 
infusion solutions. Under in-vivo conditions such an interference 
between aprotinin and heparin is not to be expected because of :he 
low aprotinin concentration in circulating blood. On the other hand, 
the combined use of aprotinin and heparin may have a beneficial 
therapeutic effect [249]. 
9.1.5. Immunoassays 
In immunodiffusion experiments the antibody should be applied to 
the gel about 4 h before aprotinin because of the rapid diffusion rate 
of the latter. Possible adsorption of aprotinin on agarose loaded with 
negatively charged groups should be borne in mind. 
9.1.6. Inhibition studies 
In inhibition assays preincubation of aprotinin with the enzyme for 
5 min (with kallikrein for 30 min) at the optimum pH of the pro-
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teirinase is generally sufficient to achieve complex formation. As a 
Ionnger incubation does not normally affect aprotinin because of its 
stahbility against proteolytic degradation, the consistency of the de-
gre<ee of inhibition reached after 5 min should be checked for a longer 
timne when an unknown proteinase is used for the first time. Apro-
tinhin-proteinase complexes dissociate at alkaline pH (> 10) and in 
acicidic solution (pH < 5, chymotrypsin and kallikrein; pH < 3, 
tryf/psin and plasmin). 
9.11.7. Use in biological studies 
At t present it is not feasible to recommend precise aprotinin concen-
tratitions sufficient for totally inhibiting proteinases in biological 
fluiiids and tissue extracts. The optimum aprotinin amount needed 
muust be determined individually in each case. However, 1 χ 10 - 5 
mool/1 (approx. 500 KIU/ml) of aprotinin should be sufficient in 
moost cases. 
Approtinin solutions should be tested for their inhibitory activity be-
fonre use. A simple trypsin inhibition assay with the substrates 
BzMrgpNA (L-BAPA) [27, 28] or BzArgOEt [33] (possibly in com­
bination with alcohol dehydrogenase and NAD [250]) is suitable for 
thiss purpose. 
9.22. Inhibition assays 
9.22.1. Photometric assay 
Α ι modification of the originally described trypsin DL-BAPA test 
[211, 27] has been reported. In this assay aprotinin inhibits the tryp-
sin-i-catalyzed hydrolysis of Ntf-benzoyl-L-arginine-p-nitroanilide 
(BzzArgpNA or L-BAPA), which is followed photometrically at 
4055 nm. One trypsin unit (UBAPA) corresponds to the hydrolysis of 
1 juumol substrate per min, i.e. a Δ A^s/min of 3.32 for a 3 ml volume 
at aa 1 cm light path. One inhibitor unit (IUBAPA) decreases the activ­
ity / of two trypsin units by 50%, which corresponds arithmetically to 
the ι inhibition of 1 UBAPA of trypsin. The specific inhibitor activity 
of aaprotinin is given in lUßAPA/mg polypeptide. 
Reaagents 
Subbstrate: 50 mg L-BAPA · HCl in 100 ml distilled water 
Bufiffer: 0.2 mol/1 triethanolamine · HCl/NaOH, 0.02 mol/1 
CaCl2, pH 7.8 
Tryypsin: 10 mg hog trypsin ( ^ 2 UßAPA/mg) or 18 mg bovine 
trypsin ( ^ 1.2 UßAPA/mg) dissolved in 100 ml 0.0025 η 
HCl, stored at 4 eC 
Inhhibitor: 10-15 mg aprotinin dissolved in 1000 ml buffer or ap­
prox. 80 KIU/ml (in the case of bovine trypsin approx. 
130 KIU/ml) 
Proocedure 
Plaace thermostated (25 °C) 3-ml cuvettes in a (spectro) photometer. 
Pippet in the following order: 0.1 ml trypsin solution, 1.8 ml buffer, 
0.1 ml inhibitor solution, each prewarmed to 25 °C; mix with a plas­
tic \ spatula and pre-incubate the mixture for 3 min. Start L-BAPA 
hyddrolysis by adding 1 ml of substrate solution, mix well and record 
the: linear (!) increase in absorbance at 405 nm for at least 5 min. 
Reppeat or make a parallel determination with buffer instead of inhi-
bitoor solution ("reference sample"). 
Calculation 
1 mnUßAPA of trypsin corresponds to a A A of 0.00332/min (reference 
sarrmple). Reduction of the trypsin activity by 50% corresponds to 0.5 
mllUßAPA aprotinin. Calculate the specific activity in IUßAPA/mg in-
hibitor. Biological units (KIU) of aprotinin may be calculated from 
the Ϊ IUBAPA by the following equation: IUBAPA χ 615 = KIU. 
If boovine trypsin ( ^ 1.2 UßAPA/mg) is used in the assay instead of 
hogg trypsin, KIU are calculated by: IUBAPA Χ 1025 = KIU. 
9.2.!.2. Titrimetric assays 
Thee proposed method is a modification of the test described pre­
viously [25, 26]. In this assay, aprotinin inhibits the trypsin-
cataalyzed hydrolysis of Να-benzoyl-L-arginine ethyl ester (BzArg-
OE£t, BAEE), and this is followed by titration of the liberated carb-
oxyyl groups (BzArgOH) with an automatic titrator or manually. 
Onee F.l.P. unit (UFIP) of trypsin corresponds to the hydrolysis of 
1 μιπιοί of substrate per min under the given conditions. One UFIP of 
aprcotinin is defined as the quantity of inhibitor which inhibits two 
UFIIIP of trypsin by 50%. 1 UFIP of aprotinin corresponds to 30 KIU 
aprcotinin, I mg pure aprotinin to approximately 238 UFIP or 7143 
KI IU . 
Reaagents 
Borrate buffer: Dissolve 572.2 mg of disodium tetraborate-10-
hyddrate and 2.94 g of calcium chloride-2-hydrate in approx. 900 ml 
distt. water. Adjust the pH to 8.00 (25 eC) with 0.1 Ν HCl, fill up 
withh dist. water to a 1000 ml final volume, and check the pH again. 
Trypsin solution: Dissolve approx. 20 mg trypsin (from pigs with a 
minimal activity of 45 Unp/mg) in 10 ml 0.001 Ν HCl, store at 
0-4 °C. This solution must be prepared daily or kept frozen until 
used. 
Substrate: Dissolve 68.56 mg BAEE · HCl in 10 ml dist. water, store 
at 0-4 °C. This solution must be prepared daily or kept frozen until 
used. 
Equipment 
pH Meter with an accuracy of 0.02 pH units; glass and calomel elec­
trodes; closable titration vessel with temperature-controlled jacket; 
magnetic stirrer; temperature-controlled heating unit for the reac­
tion vessels (25 ± 0.1 °C); 0.5 ml microburettes; in addition, for 
automatic titration a control unit for pH state titration, a 0.25 ml 
motor burette, and a recorder. Complete titration units are supplied 
by several companies, e.g. Radiometer, Copenhagen, and Metrohm, 
Herisau. 
Procedure 
Preincubation samples 
Use an aprotinin solution containing approx. 1000 KIU/ml. Prepare 
the following mixtures in 5 ml tubes: 
(a) 3.9 ml borate buffer, 0.1 ml trypsin solution (reference sample); 
(b) 3.5 ml borate buffer, 0.2 ml trypsin solution, 0.3 ml aprotinin 
solution (inhibitor test sample). 
Close the tubes, shake and incubate for 10 min at 25 °C. 
Automatic titration: Fill 1.8 ml of borate buffer and 0.2 ml of sub­
strate solution into the titration vessel and stir for 5 min to maintain 
constant temperature. Adjust the pH to 8.00 by addition of 0.02 Ν 
NaOH and add quickly 0.2 ml of either sample (a) or (b). Maintain 
the pH between 7.95 and 8.05 by continuous addition of 0.02 Ν 
NaOH. Record the NaOH consumption for at least 6 min. 
Manual titration: Fill 9.0 ml of borate buffer and 1.0 ml of substrate 
solution into the titration vessel and stir as for 5 min to maintain 
constant temperature. Adjust the pH to 8.00 by addition of 0.1 Ν 
NaOH and add quickly 1.0 ml of either sample (a) or (b); at the 
same time start a stopwatch. Maintain the pH between 7.95 and 
8.05 by continuous addition of 0.1 Ν NaOH. Record the NaOH 
consumption for at least 6 min. 
Repeat each test at least once. 
Calculation of units 
Determine the NaOH consumption per min graphically from the 
titration curve (aut, automatic titration; man, manual titration): 
U (μηηοΐ/min) = or 
U = μπιοί NaOH consumed per min; 
V = volume of NaOH consumed during test; 
t = test time in min. 
Calculate the biological units by the formula: 
(2 U r e f - U i n h ) x 4 χ Fx 30 KIU/ml = -
0.3 xc 
Uref = activity of reference sample; 
Uinh = activity of inhibitor test sample; 
F = dilution factor; 
c = volume in ml of pre-incubation sample (a) or (b), cf. Proce­
dure. 
For each U r e f and Uinh, mean values of 4 determinations should be 
used. 
The numerical proportion of the values U r e f and Uinh should be be­
tween 0.8 and 1.2. 
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